Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Ruoan kotiinkuljetus diabeteksen hoitoon maaseutuklinikan potilaille

perjantai 21. elokuuta 2026 päivittänyt: University of Arkansas

Pitkän tähtäimen tavoitteemme on muuttaa maaseudun asukkaiden T2DM-johtamista. Tämän tutkimuksen tavoitteena on määrittää sellaisen toimenpiteen tehokkuus, joka on skaalautuva ja kestävä ja edistää potilaiden hoitoon sitoutumista vähentämällä maaseudun elintarviketurvasta kärsivien osallistujien vaikeuksia, jotka liittyvät olemassa olevien toimenpiteiden loppuun saattamiseen. Erityistavoitteemme ovat:

  1. Vertaa Healthy Food Delivery Intervention (HFDI) tehokkuutta sekä tavanomaista hoitoa ja standardihoitoa yksinään parantaaksesi diabetekseen liittyviä tuloksia maaseudun elintarviketurvattomilla T2DM-potilailla. Hypoteesi: Verrattuna pelkkään tavanomaiseen hoitoon HFDI:tä plus standardihoitoa saavat potilaat osoittavat parantuneen: H1-glykeemisen hallinnan HbA1c:llä mitattuna; H2:n kardiometaboliset riskitekijät: verenpaine, paastoglukoosi, paastolipidit ja BMI; H3 itsehallinta: itsetehokkuus, itsehoitokäyttäytymisten noudattaminen ja lääkityksen noudattaminen; H4 potilaskeskeiset tulokset: diabetekseen liittyvä ahdistus, diabetekseen liittyvä elämänlaatu ja diabetekseen liittyvät komplikaatiot.
  2. Vertaa HFDI:n tehokkuutta sekä tavallisen hoidon ja pelkän tavanomaisen hoidon tehokkuutta parantaaksesi ruokavalion laatua maaseudun ruoasta epävarmojen T2DM-potilaiden keskuudessa. Hypoteesi: Pelkästään tavanomaiseen hoitoon verrattuna HFDI:tä plus standardihoitoa saavat potilaat osoittavat parantuneet: H1 Healthy Eating Index 2015 (HEI-2015) -pisteet; H2 hedelmien ja vihannesten kulutus.
  3. Vertaile kustannustehokkuutta ymmärtääksesi HFDI:n ja tavanomaisten hoitokustannusten suhteessa tuloksiin verrattuna pelkkään tavalliseen hoitoon. Hypoteesi: HFDI on kustannustehokas perustuen perinteisiin kustannuksiin jokaista ylimääräistä laatukorjattua elinvuotta kohti.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.

This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.

The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.

Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.

Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.

Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.

Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.

Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.

Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

416

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Arkansas
      • Batesville, Arkansas, Yhdysvallat, 72501
        • UAMS - North Central
      • Corning, Arkansas, Yhdysvallat, 72422
        • Pocahontas Medical Center
      • Eureka Springs, Arkansas, Yhdysvallat, 72632
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Yhdysvallat, 72703
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Yhdysvallat, 72703
        • UAMS - Northwest
      • Fort Smith, Arkansas, Yhdysvallat, 72901
        • UAMS - West
      • Harrison, Arkansas, Yhdysvallat, 72601
        • Washington Regional Medical Center
      • Helena, Arkansas, Yhdysvallat, 72390
        • UAMS - East
      • Jonesboro, Arkansas, Yhdysvallat, 72401
        • UAMS - Northeast
      • Magnolia, Arkansas, Yhdysvallat, 71753
        • UAMS - South
      • Marianna, Arkansas, Yhdysvallat, 72360
        • Lee County Cooperative Clinic
      • Marshall, Arkansas, Yhdysvallat, 72650
        • Boston Mountain Rural Health Center
      • Pocahontas, Arkansas, Yhdysvallat, 72455
        • Pocahontas Medical Clinic

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Sisällyttämiskriteerit:

  • 18 vuotta täyttänyt tai vanhempi
  • ilmoittaa elintarviketurvasta
  • raportti T2D (vahvistettu, että HbA1c on 6,5 tai suurempi ensimmäisellä tiedonkeruulla välittömästi suostumuksen jälkeen)
  • Puhu englantia tai espanjaa
  • Asuu tällä hetkellä maaseudulla

Poissulkemiskriteerit:

  • olosuhteet, joiden vuoksi on epätodennäköistä, että osallistuja pystyy noudattamaan protokollaa, kuten terminaalinen sairaus, vakava mielisairaus, vakava näkö- tai kuulohäiriö, syömishäiriö tai suunnitelmat muuttaa pois maantieteelliseltä alueelta
  • Raskaana

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Tukevaa hoitoa
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Kokeellinen: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Hemoglobin A1c (HbA1c)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Diet Quality: Healthy Eating Index-2015 Score
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks)
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software. The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations. HEI-2015 consists of 13 individual components. HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks)
Diet Quality: Veggie Meter Score
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy. The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption. Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis. Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Body Mass Index (BMI)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale. Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Systolic Blood Pressure (SBP)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diastolic Blood Pressure (DBP)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Total Cholesterol
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
High-Density Lipoproteins (HDL)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Low-Density Lipoproteins (LDL)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Triglycerides
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Glucose
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes Self-Efficacy (DMSES)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes. The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes. The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes-Related Distress (PAID-5)
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress. The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed. Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food Insecurity
Aikaikkuna: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food insecurity was assessed using the 2-item Hunger Vital Sign. Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity. Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Pearl A McElfish, PhD, University of Arkansas

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 22. lokakuuta 2021

Ensisijainen valmistuminen (Todellinen)

Torstai 6. helmikuuta 2025

Opintojen valmistuminen (Todellinen)

Torstai 18. joulukuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 30. huhtikuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 5. toukokuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Torstai 6. toukokuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 16. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 21. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muut tutkimustunnusnumerot

  • 261074
  • 5R01NR019487 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa